In contrast, SUMO-C1 was mainly enriched in tumor immune-related processes, such as TNFA signaling via NF-κB, IL6-STAT3 signaling, complement, inflammatory response, and IL2-STAT5 signaling, allograft rejection signaling pathway. This evidence concerns the gene IL2 and neoplasm.